• Explore /
  • Poster
  • / A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.

A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.

Abstract Poster

Authors

Benjamin Weinberg

Benjamin Adam Weinberg

Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

Benjamin Adam Weinberg , Hongkun Wang , Agnieszka Katarzyna Witkiewicz , John Marshall , Erik S. Knudsen , Michael J. Pishvaian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT02985125

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS4150)

DOI

10.1200/JCO.2018.36.15_suppl.TPS4150

Abstract #

TPS4150

Poster Bd #

329b

Abstract Disclosures

Similar Posters

First Author: Shipra Gandhi

First Author: John Paul Y.C. Shen

First Author: Ronan Joseph Kelly

First Author: Sherry Shen